Provider Connections: Dr. Stephen Ansell on Relapsed/Refractory Hodgkin Lymphoma скачать в хорошем качестве

Provider Connections: Dr. Stephen Ansell on Relapsed/Refractory Hodgkin Lymphoma

Special thanks to Goldman Philanthropic Partnerships for funding this series. Introduction to Second-Line Hodgkin Lymphoma Therapy Introduction to Dr. Steve Ansell, a hematologist at Mayo Clinic and the topic of second-line and subsequent treatment options for patients with Hodgkin lymphoma. Three-Step Treatment Strategy This section outlines the general principles of second-line treatment, which are broken down into three main phases, salvage treatment to reduce the cancer to a low level, an autologous stem cell transplant to intensify treatment and further eliminate cancer cells, consolidation treatment to maintain the benefit and prevent relapse in high-risk patients, and a fourth category of additional options for patients who relapse again. Salvage Chemotherapy and Targeted Drugs Salvage chemotherapy uses different drugs than those in the frontline treatment. This therapy is often combined with novel, targeted drugs such as brentuximab vedotin (targets CD30) or nivolumab and pembrolizumab (target PD-1 and activate the immune system). The goal is to shrink the cancer and get it under control before the next step. Autologous Stem Cell Transplant Explained Process of an autologous stem cell transplant. "Autologous" means the patient's own bone marrow is used. Stem cells are collected and frozen. The patient then receives high-dose chemotherapy to kill the remaining cancer cells, and the stored stem cells are re-infused to regenerate the bone marrow. This intensive treatment is a key step in pursuing a cure. Consolidation Treatment for High-Risk Patients For patients at high risk of relapse (e.g., those who had a poor response to initial therapy or whose cancer returned quickly). This typically involves using drugs like brentuximab vedotin or radiation therapy to bulky tumor areas to maintain the treatment's benefits and reduce the chance of the cancer coming back. Options for Stubborn or Relapsed Disease Treatment options for the rare cases where the cancer returns even after intensive therapies like a stem cell transplant. These options include PD-1 blocking antibodies (pembrolizumab or nivolumab), other immune checkpoint inhibitors, and newer therapies being tested in clinical trials, such as CAR-T cells or bispecific antibodies. Conclusion and Key Takeaways Reinforcing that multiple effective therapies exist for Hodgkin lymphoma and that the ultimate goal, even in second-line treatment, is a cure. Acknowledgments The video ends with acknowledgements to the patients, the Mayo Clinic Lymphoma Disease-Oriented Group, and the Goldman Philanthropic Partnerships for their donation that funded the educational series. Quick timestamps: 00:00 - Introduction to Second-Line Hodgkin Lymphoma Therapy 01:24 - Three-Step Treatment Strategy 02:21 - Salvage Chemotherapy and Targeted Drugs 03:09 - Autologous Stem Cell Transplant Explained 04:09 - Consolidation Treatment for High-Risk Patients 05:39 - Options for Stubborn or Relapsed Disease 06:45 - Conclusion and Key Takeaways 07:15 - Acknowledgments Visit Mayo Clinic: https://mayocl.in/2COVmlm Like Mayo Clinic on Facebook:   / mayoclinic   Follow Mayo Clinic on Instagram:   / mayoclinic   Follow Mayo Clinic on X, formerly Twitter: https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic